2024/05/23 06:07 1/2 Aniuzaline

Aniuzaline

A drug created and manufactured by Advancer Enterprises, it entered Advancer's pharmaceutical catalog in late YE 45. Aniuzaline is an advanced haemostatic drug, developed to control excessive bleeding, especially in traumatic injury scenarios.

| »Optional Image« | | |
|--------------------------|---|--|
| Year Created: YE 45 | | |
| Designer / Manufacturer: | Advancer Enterprises | |
| Nomenclature: | AE-N2 | |
| Price: | 50 KS per 5ml gel tube or injectable vial | |

History

Aniuzaline was conceived to fill a critical gap in emergency medicine, specifically for rapid haemostatic intervention in both military and civilian contexts. The drug was fast-tracked through the development pipeline, receiving priority status for clinical trials. It was a collaborative triumph, involving experts from various medical disciplines including trauma surgery, haematology, and pharmacology. The drug was particularly aimed at benefiting non NH-series lifeforms such as Kodians, thereby broadening its applicability and fulfilling Advancer's commitment to inclusive healthcare solutions.

Usage

Aniuzaline is available in two forms: a 5ml gel tube for topical application and a 5ml injectable vial for deeper wounds. The drug works by accelerating the body's natural clotting mechanisms, specifically enhancing platelet aggregation and the activity of clotting factors. A single application or injection of 5ml is the standard dosage, sufficient for most emergency scenarios. In extreme cases, a second application may be administered, but only under strict medical supervision. The pricing reflects the drug's specialized nature and is set at 60 KS per 5ml tube or vial.

Side Effects

While Aniuzaline is a medical marvel in emergency haemostasis, it is not without its risks. The drug's potent clotting ability can, if misused, lead to the formation of dangerous blood clots, potentially causing conditions like deep vein thrombosis or pulmonary embolism. More severe complications could include stroke or heart attacks. Given these risks, it is imperative that Aniuzaline is administered only under qualified medical supervision.

Last update: 2024/03/13 00:35

Overdose

An overdose of Aniuzaline is a serious medical emergency. It can lead to localized disseminated intravascular coagulation (DIC), a condition characterized by excessive clotting that can rapidly escalate to multi-organ failure. An overdose is generally defined as the application of more than two 5ml doses to a single wound within a short time frame. Immediate intervention, including the use of anticoagulants, is essential to counteract the drug's effects and prevent further complications.

OOC Notes

Demibear created this article on 2023/10/08 23:37.

Approval Thread:

https://stararmy.com/roleplay-forum/threads/advancer-enterprises-white-lion-type-45-vehicle-aid-kit.7105 1/

| Drugs, Medicines, and Pharmaceuticals | | |
|---------------------------------------|-----------------------|--|
| Drug Name(s) | Aniuzaline | |
| Route of Administration | local, topical (skin) | |
| Drug Class | Stem cell stimulator | |

| Products & Items Database | | |
|---------------------------|----------------------|--|
| Product Categories | drugs | |
| Product Name | Aniuzaline | |
| Nomenclature | AE-N2 | |
| Manufacturer | Advancer Enterprises | |
| Year Released | YE 45 | |
| Price (KS) | 50.00 KS | |

From:

https://wiki.stararmy.com/ - STAR ARMY

Permanent link:

https://wiki.stararmy.com/doku.php?id=items:drugs:aniuzaline

Last update: 2024/03/13 00:35

